Advances in Peptide-Functionalized Polymeric Nanocarriers for Cancer Therapy

Background/Objectives: Peptide-functionalized polymeric nanocarriers are redefining targeted cancer therapy by combining the molecular specificity of peptides with the structural versatility of polymers. This review aims to highlight recent advances in peptide-functionalized polymeric nanocarrier systems designed to overcome key biological barriers to effective drug delivery. Methods: This review examines peptide-functionalized polymeric nanocarriers, including polymeric nanoparticles, micelles, polyplexes, and polymer–drug conjugates engineered with targeting, cell-penetrating, tumor-penetrating, and tumor microenvironment-responsive peptides. Emerging design strategies, including dual- and multi-peptide functionalization, stimuli-responsive linkers, and prodrug-like polymer architectures, are reviewed. Results: These peptide-functionalized polymeric nanocarrier systems have been investigated for the delivery of diverse therapeutic cargos, including small-molecule drugs, peptides, proteins, and nucleic acids. They demonstrate enhanced tumor localization, improved cellular internalization, and spatiotemporally controlled drug release, thereby contributing to significantly improved therapeutic efficacy and reduced systemic toxicity in preclinical studies. Advanced designs incorporating multiple peptide functionalities further enable precise modulation of drug delivery and therapeutic outcomes. Conclusions: Peptide-functionalized polymeric nanocarriers represent a versatile and powerful platform for next-generation cancer therapeutics. However, challenges related to stability, large-scale manufacturability, and clinical translation persist. Integration of data-driven approaches and artificial intelligence holds promise for accelerating optimization and facilitating clinical translation.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-09-28
DOI
https://doi.org/10.3390/pharmaceutics18101231
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Advances in Peptide-Functionalized Polymeric Nanocarriers for Cancer Therapy

Divya V. Kamath, Obdulia Covarrubias‐Zambrano, Ojaswitha Ommi, Stefan H Bossmann
Pharmaceutics
RNA Interference and Gene Delivery
article

Advances in Peptide-Functionalized Polymeric Nanocarriers for Cancer Therapy

Divya V. Kamath, Obdulia Covarrubias‐Zambrano, Ojaswitha Ommi, Stefan H Bossmann
article en

Abstract

Background/Objectives: Peptide-functionalized polymeric nanocarriers are redefining targeted cancer therapy by combining the molecular specificity of peptides with the structural versatility of polymers. This review aims to highlight recent advances in peptide-functionalized polymeric nanocarrier systems designed to overcome key biological barriers to effective drug delivery. Methods: This review examines peptide-functionalized polymeric nanocarriers, including polymeric nanoparticles, micelles, polyplexes, and polymer–drug conjugates engineered with targeting, cell-penetrating, tumor-penetrating, and tumor microenvironment-responsive peptides. Emerging design strategies, including dual- and multi-peptide functionalization, stimuli-responsive linkers, and prodrug-like polymer architectures, are reviewed. Results: These peptide-functionalized polymeric nanocarrier systems have been investigated for the delivery of diverse therapeutic cargos, including small-molecule drugs, peptides, proteins, and nucleic acids. They demonstrate enhanced tumor localization, improved cellular internalization, and spatiotemporally controlled drug release, thereby contributing to significantly improved therapeutic efficacy and reduced systemic toxicity in preclinical studies. Advanced designs incorporating multiple peptide functionalities further enable precise modulation of drug delivery and therapeutic outcomes. Conclusions: Peptide-functionalized polymeric nanocarriers represent a versatile and powerful platform for next-generation cancer therapeutics. However, challenges related to stability, large-scale manufacturability, and clinical translation persist. Integration of data-driven approaches and artificial intelligence holds promise for accelerating optimization and facilitating clinical translation.

PharmaceuticsVol. 18(10)
The University of Kansas Cancer Center (US), University of Kansas Medical Center (US)
Good health and well-being
Openalex Percentile: Top 19%
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.